Shengcaofeng Health Industry (Yunnan) Co., Ltd was AiXin Life International’s largest revenue line in fiscal 2025, bringing in $656.62K of $665.79K (99%).
| Related and Nonrelated Parties | FY 2025 |
|---|---|
| Shengcaofeng Health Industry (Yunnan) Co., Ltd | $656.62K |
| Chengdu Aixin International Travel Service Co., Ltd | $4.68K |
| Sichuan Aixintang Xinfu Pharmacy Chain Co., Ltd | $3.71K |
| Chengdu Lisheng Huiren Pharmacy Co., Ltd | $785 |
| Total | $665.79K |
AiXin Life International brought in $665.79K from its four revenue lines in fiscal 2025, the year ended December 31, 2025. Shengcaofeng Health Industry (Yunnan) Co., Ltd was the largest at $656.62K (98.6%), ahead of Chengdu Aixin International Travel Service Co., Ltd at $4.68K (0.7%) and Sichuan Aixintang Xinfu Pharmacy Chain Co., Ltd at $3.71K (0.6%). The remaining revenue line, Chengdu Lisheng Huiren Pharmacy Co., Ltd, brought in $785.
Manufacture & Sale was AiXin Life International’s largest product and service line in fiscal 2024, bringing in $1.91M of $4.33M (44%).
| Product and Service | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|---|---|
| Advertising | $1.94M | — | — | — | |||
| Manufacture & Sale | — | $238.40K | $798.18K | $1.91M | |||
| Product | $742.62K | — | $1.16M | $504.10K | |||
| Hotel | — | — | $1.19M | $585.63K | |||
| Pharmacy | — | — | — | $822.96K | |||
| Pharmacies | — | $789.35K | $937.66K | — | |||
| Direct Sales | — | — | $1.16M | $504.10K | |||
| Products | — | $823.93K | — | — | |||
| Food & Beverage Revenues | $201.76K | $475.75K | — | — | |||
| Room Revenue | $114.09K | $262.61K | — | — | |||
| Other | $62.96K | $118.53K | — | — | |||
| Total | $3.07M | $2.71M | $5.25M | $4.33M |
AiXin Life International brought in $4.33M from its five product and service lines in fiscal 2024, the year ended December 31, 2024. AiXin Life International regrouped these lines after fiscal 2023, so the total does not compare directly with that year's $5.25M. Manufacture & Sale was the largest at $1.91M (44.2%), ahead of Pharmacy at $822.96K (19.0%) and Hotel at $585.63K (13.5%). The other two lines brought in $1.01M combined.
Compared with fiscal 2023, Manufacture & Sale grew fastest, up 139.5% to $1.91M, while Direct Sales fell the most, down 56.5% to $504.10K.
AiXin Life International began breaking out Manufacture & Sale in fiscal 2022, Hotel in fiscal 2023, Pharmacy in fiscal 2024 and Direct Sales in fiscal 2023. AiXin Life International stopped reporting Advertising ($1.94M in fiscal 2021), Pharmacies ($937.66K in fiscal 2023), Products ($823.93K in fiscal 2022) and three others as separate lines.
AiXin Life International (AIXN) reports its revenue by related and nonrelated parties and by product and service. In fiscal 2025, Shengcaofeng Health Industry (Yunnan) Co., Ltd was its largest revenue line, bringing in $656.62K (98.6% of the total), followed by Chengdu Aixin International Travel Service Co., Ltd at $4.68K (0.7%).
Shengcaofeng Health Industry (Yunnan) Co., Ltd was AiXin Life International's largest revenue line in fiscal 2025, bringing in $656.62K, or 98.6% of the $665.79K total across its four revenue lines.
Manufacture & Sale was AiXin Life International's largest product and service line in fiscal 2024, bringing in $1.91M, or 44.2% of the $4.33M total across its five product and service lines.
Every figure comes from AiXin Life International's annual financial filings, as reported. Each line keeps the name AiXin Life International gives it, and years follow its fiscal calendar.
AiXin Life International's revenue by related and nonrelated parties goes back to fiscal 2025, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.